What question did this study set out to answer?

The research aims to explore IRF3's role in innate immune-driven corneal inflammation and its potential as a therapeutic target.

March 25, 2026Open Access

Interferon Regulatory Factor 3 as a Mediator and Therapeutic Target in Innate Immune-Driven Corneal Stromal Inflammation and Opacity

Key Points

The research aims to explore IRF3's role in innate immune-driven corneal inflammation and its potential as a therapeutic target.
Utilized genetic and pharmacologic approaches to inhibit IRF3
Measured cytokine and myeloid responses following IRF3 inhibition
Evaluated the effects of piceatannol as a potential therapy
Inhibition of IRF3 reduced cytokine production
Decreased myeloid immune responses were observed
Piceatannol offered a therapeutic avenue for maintaining corneal clarity

Abstract

IRF3 is a pivotal regulator of innate immune-driven stromal inflammation and opacity. Both genetic and pharmacologic inhibition of IRF3 attenuated cytokine and myeloid responses, suggesting that targeting IRF3, potentially via piceatannol (PIC), offers a therapeutic strategy for preserving corneal transparency.

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Lee et al. (Mon,) studied this question.

synapsesocial.com/papers/69c37b54b34aaaeb1a67d981 https://doi.org/https://doi.org/10.1167/iovs.67.3.49

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI से पूछें

Bookmark

View Full Paper